Latest:
Moffitt Study Reveals Way to Spark Immune Hotspots That Attack Tumors
Investigators at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary lymphoid-like structures.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Matthew Manning, MD
Latest:
Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.
Stacey Stein, MD
Latest:
Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC
Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.
Ashley Sumrall, MD
Latest:
Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas
Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida
Latest:
Patient Perspectives From the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)
Sikander Ailawadhi, MD, reviews patient experience and satisfaction findings from the phase 3 IRAKLIA study comparing subcutaneous isatuximab via on-body injector with intravenous isatuximab in relapsed or refractory multiple myeloma.